


Healthcare | Small Cap
Alembic Pharmaceuticals Ltd. showcases a robust financial profile characterized by impressive growth, high profitability, and exceptional financial stability. The company's very low reliance on debt is a significant strength, providing a solid foundation and minimizing financial risk. This has enabled strong performance in both revenue and profit growth, indicating successful market strategies. Returns for shareholders are also strong. However, the company faces challenges in its operational efficiency. It takes a considerable amount of time to sell inventory and collect payments from customers, which can strain cash flow. While its ability to meet short-term obligations is generally adequate, its immediate cash reserves are low. The future outlook appears positive, driven by its financial strength and growth momentum, though operational effectiveness is a key area to monitor.
Alembic Pharmaceuticals Ltd. showcases a robust financial profile characterized by impressive growth, high profitability, and exceptional financial stability. The company's very low reliance on debt is a significant strength, providing a solid foundation and minimizing financial risk. This has enabled strong performance in both revenue and profit growth, indicating successful market strategies. Returns for shareholders are also strong. However, the company faces challenges in its operational efficiency. It takes a considerable amount of time to sell inventory and collect payments from customers, which can strain cash flow. While its ability to meet short-term obligations is generally adequate, its immediate cash reserves are low. The future outlook appears positive, driven by its financial strength and growth momentum, though operational effectiveness is a key area to monitor.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
25.70
Industry Median
32.38
Small Cap Median
29.54
P/E RATIO
24.39
P/B RATIO
2.90
Industry Median
3.38
Small Cap Median
2.89
P/S RATIO
2.30
Industry Median
3.65
Small Cap Median
2.73
Others
PEG RATIO
-2.40
EV/EBITDA RATIO
15.23
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹837.4 as on Jul 11, 2026.
The company is on an outstanding growth trajectory. It has demonstrated exceptional performance across all key growth indicators, including a strong rebound in sales and a significant increase in profitability. Earnings for shareholders have also expanded robustly. This comprehensive growth signals strong market demand for its products, effective business strategies, and successful execution. This upward trend is a major positive, indicating a healthy, expanding business that is likely increasing its market share and creating substantial value.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -1.61 | 6.54 | 10.19 | 7.11 | 10.09 |
| Operating Profit Growth Rate | -40.95 | -21.97 | 36.66 | 8.15 | 10.91 |
| Earnings Per Share (EPS) Growth | -54.57 | -34.34 | 80.06 | -5.27 | 15.67 |
| Asset Growth Rate | 6.16 | -13.18 | 4.25 | 20.59 | 12.74 |
| Net Income Growth Rate | -54.54 | -34.36 | 80.12 | -5.52 | 15.29 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 55.11 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Neuland Laboratories Ltd | 7.84 | 68.75 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 3 | Granules India Ltd | 7.73 | 37.06 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 4 | Alembic Pharmaceuticals Ltd | 7.60 | 24.39 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 5 | Emcure Pharmaceuticals Ltd | 7.40 | 37.21 | Neutral | 1865.00 | 38.64 | 941.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 29.54 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Syngene International Ltd | 7.16 | 53.48 | Overvalued | 918.00 | 7.55 | 317.00 |
| 8 | ERIS Lifesciences Ltd | 7.15 | 32.00 | Neutral | 1120.00 | 17.61 | 648.00 |
| 9 | Piramal Pharma Ltd | 5.83 | -72.31 | Neutral | 922.00 | 5.26 | -326.00 |
| 10 | Jubilant Pharmova Ltd | 5.71 | 38.54 | Neutral | 1260.00 | 1.25 | 398.00 |
| 11 | Natco Pharma Ltd | 5.69 | 12.43 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 12 | Strides Pharma Science Ltd | 5.55 | 17.94 | Undervalued | 925.00 | 19.92 | 575.00 |
| 13 | Jeena Sikho Lifecare Ltd | 5.52 | 33.22 | Neutral | 349.00 | 17.87 | 222.00 |
| 14 | Wockhardt Ltd | 5.07 | 138.12 | Neutral | 652.00 | 19.51 | 199.00 |
| 15 | Pfizer Ltd | 3.45 | 47.13 | Neutral | -82.00 | 157.92 | 300.00 |
| 16 | Procter & Gamble Health Ltd | 3.45 | 34.73 | Neutral | 457.00 | 196.94 | 327.00 |
| 17 | Sanofi India Ltd | 3.45 | 18.93 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT